+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

A

Actively Recruiting

Transthyretin Amyloid Cardiomyopathy ATTR-CM is a serious heart condition caused by the buildup of misfolded transthyretin protein in the heart muscle, leading to heart stiffness and progressive heart failure. There are two types a hereditary form and a wild-type form related to aging. Diagnosing ATTR-CM can be challenging because its symptoms resemble other heart diseases, but advances in medical imaging have improved early detection. Acoramidis is a new medication designed to stabilize the transthyretin protein and prevent harmful buildup. The ACO-REAL study is an observational research project aiming to collect real-world data on acoramidis use in patients with ATTR-CM. This study will observe adults diagnosed with either wild-type or variant ATTR-CM who are starting acoramidis treatment as part of their routine care in approximately 20 European countries. It includes patients new to treatment as well as those who have received other therapies. Researchers will document patient characteristics, how acoramidis is used in everyday clinical practice, and any side effects. The study does not introduce experimental treatments but follows patients receiving acoramidis according to normal medical standards. Participants will be followed for about 12 to 15 months after starting acoramidis. Researchers will collect data on heart function, functional capacity like walking ability, overall health, quality of life, and healthcare usage such as hospital visits. They will also monitor for adverse events during this period. This information aims to improve understanding of ATTR-CM and optimize patient care in real-world settings.

Age: 18Years +All Genders
17 locations
R

Actively Recruiting

Researchers are observing how men with metastatic hormone-sensitive prostate cancer mHSPC respond to treatment with darolutamide combined with androgen deprivation therapy ADT, with or without the chemotherapy drug docetaxel. This international, open-label, multi-cohort study aims to understand the real-world effectiveness and safety of these treatments in routine medical practice. The study will enroll about 1,600 male patients primarily from Europe, focusing on those already decided to receive darolutamide before joining the study. Participants will be divided into two groups one receiving darolutamide plus ADT and docetaxel triplet therapy, and the other receiving darolutamide plus ADT without docetaxel doublet therapy. Treatment is given according to local standard care and chosen by the treating physician. No additional study-specific treatments or procedures are required, as data is collected during routine care visits over the study period. During the study, researchers will collect data on prostate-specific antigen PSA levels, survival rates, time to new treatments, progression of disease, adverse events, quality of life, and other clinical information. Data collection is done via electronic records during regular doctor visits with no extra tests beyond standard care. The study will last up to four years with periodic analyses to help improve understanding of darolutamide use in everyday clinical settings.

Age: 18Years +MALE
16 locations
O

Actively Recruiting

Researchers are observing children aged 7 to under 12 years with mild, moderate, or severe hemophilia A who are receiving damoctocog alfa pegol. This study aims to learn more about how this treatment works in preventing bleeding episodes during routine medical care. Participants have previously been treated with damoctocog alfa pegol or other factor VIII products, and the study focuses on their usual treatment without any changes or advice from the study team. Participants receive damoctocog alfa pegol as prescribed by their own doctors for regular continuous prophylaxis to prevent bleeding. The study collects data from routine medical care and does not require additional visits or tests. Historical medical records and interviews with patients and their guardians provide background information. Guardians also keep a health diary to record bleeding episodes and treatment, and complete questionnaires assessing the impact of hemophilia on daily life. Data collection occurs over two years or until participants leave the study or change treatment. Researchers track the number and type of bleeding episodes, treatment details including dosing and infusions, and overall health status. The main outcome measures include the number of treated bleeds documented in diaries. No extra procedures are needed beyond routine care, and the study monitors how damoctocog alfa pegol is used in real-world settings.

Age: 7Years - 12YearsAll Genders
12 locations